Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hongnan Mo

Showing results (21-30 of 54) with videos related to

Pageof 6
Sort By:
Patient Preference and Adherence|June 23, 2026
Sleep Disturbance, Treatment-Related Adverse Events, and Psychological Distress in Breast Cancer Patients: A Prospective Cohort StudyFang Zhao, Yuqiu Li, Yanjun Zhou, et al.
Therapeutic Advances in Medical Oncology|September 11, 2024
Inetetamab-based therapy in real-world treatment patterns with HER2-positive advanced breast cancer patients: a retrospective single-center studyMingxia Jiang, Jiaxuan Liu, Maiyue He, et al.
Clinical Rheumatology|November 23, 2017
Red blood cell distribution width as a related factor of pulmonary arterial hypertension in patients with systemic sclerosisJiuliang Zhao, Hongnan Mo, Xiaoxiao Guo, et al.
Translational Oncology|November 2, 2024
Comparative efficacy of anthracycline-free and anthracycline-containing neoadjuvant chemoimmunotherapy regimens for triple-negative breast cancerYuhan Wei, Qiao Li, Hongnan Mo, et al.
Molecular Cancer|August 30, 2022
S6K1 amplification confers innate resistance to CDK4/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancerHongnan Mo, Xuefeng Liu, Yu Xue, et al.
BMC Cancer|October 18, 2024
Pyrotinib combined with metronomic etoposide in heavily pretreated HER2-positive metastatic breast cancer: a single-arm, phase II studyJiaxuan Liu, Maiyue He, Mingxia Jiang, et al.
Oncotarget|July 23, 2016
Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trialPin Zhang, Yi Yin, Hongnan Mo, et al.
Signal Transduction and Targeted Therapy|July 7, 2021
The molecular tumor burden index as a response evaluation criterion in breast cancerZongbi Yi, Fei Ma, Guohua Rong, et al.
Journal for Immunotherapy of Cancer|June 23, 2025
STS2 deficiency revives CD8<sup>+</sup>T cells from exhaustion and augments checkpoint blockade efficacy in cancer immunotherapyFangzhou Sun, Fei Ma, Ting Wang, et al.
Annals of Translational Medicine|February 11, 2021
Comparison of capecitabine-based regimens with platinum-based regimens in Chinese triple-negative breast cancer patients with liver metastasisYimeng Chen, Yin Guan, Jiayu Wang, et al.
Pageof 6

Showing results (21-30 of 54) with videos related to

Sort By:
Pageof 6
Patient Preference and Adherence|June 23, 2026
Sleep Disturbance, Treatment-Related Adverse Events, and Psychological Distress in Breast Cancer Patients: A Prospective Cohort StudyFang Zhao, Yuqiu Li, Yanjun Zhou, et al.
Therapeutic Advances in Medical Oncology|September 11, 2024
Inetetamab-based therapy in real-world treatment patterns with HER2-positive advanced breast cancer patients: a retrospective single-center studyMingxia Jiang, Jiaxuan Liu, Maiyue He, et al.
Clinical Rheumatology|November 23, 2017
Red blood cell distribution width as a related factor of pulmonary arterial hypertension in patients with systemic sclerosisJiuliang Zhao, Hongnan Mo, Xiaoxiao Guo, et al.
Translational Oncology|November 2, 2024
Comparative efficacy of anthracycline-free and anthracycline-containing neoadjuvant chemoimmunotherapy regimens for triple-negative breast cancerYuhan Wei, Qiao Li, Hongnan Mo, et al.
Molecular Cancer|August 30, 2022
S6K1 amplification confers innate resistance to CDK4/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancerHongnan Mo, Xuefeng Liu, Yu Xue, et al.
BMC Cancer|October 18, 2024
Pyrotinib combined with metronomic etoposide in heavily pretreated HER2-positive metastatic breast cancer: a single-arm, phase II studyJiaxuan Liu, Maiyue He, Mingxia Jiang, et al.
Oncotarget|July 23, 2016
Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trialPin Zhang, Yi Yin, Hongnan Mo, et al.
Signal Transduction and Targeted Therapy|July 7, 2021
The molecular tumor burden index as a response evaluation criterion in breast cancerZongbi Yi, Fei Ma, Guohua Rong, et al.
Journal for Immunotherapy of Cancer|June 23, 2025
STS2 deficiency revives CD8<sup>+</sup>T cells from exhaustion and augments checkpoint blockade efficacy in cancer immunotherapyFangzhou Sun, Fei Ma, Ting Wang, et al.
Annals of Translational Medicine|February 11, 2021
Comparison of capecitabine-based regimens with platinum-based regimens in Chinese triple-negative breast cancer patients with liver metastasisYimeng Chen, Yin Guan, Jiayu Wang, et al.
Pageof 6